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Abstract
Stem cell therapy or “cell therapy” has been demonstrated to be a potent treatment intervention in animal models
of acute ischemic stroke, and recently has been introduced as an experimental therapy in early phase clinical trials.
Among the many stem cells, the bone marrow adherent cell type known as mesenchymal stem cells have emerged
in laboratory studies as a safe and effective therapy for ischemic stroke and other brain diseases. In particular, a unique
population of adherent bone marrow-derived cells, called MultiStem cells, display immunomodulatory effects and are
a promising allogeneic cell therapy in acute ischemic stroke. Here, we describe the preclinical evidence supporting the
use of MultiStem in the acute setting of ischemic stroke and the translation into an early phase clinical trial in ischemic
stroke.
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Background
Stroke is still a primary cause of mortality and morbidity
in developed countries [1, 2]. Despite the advent of
thrombolytic therapy as a stroke treatment, the limited
therapeutic window only benefits a small number of
stroke patients. Of note, tissue plasminogen activator
(tPA), which is the only approved drug by US Food &
Drug Administration, needs to be administered to ische-
mic stroke patients within three hours [3]. Even those
who receive such thrombolytic treatment display signifi-
cant disability following 3 months of stroke onset. In
accordance with the ECASS 3 trial and the American
Stroke Association advisory panel, the window for treat-
ment has been extended to 4.5-hours. However, despite
the expansion of the tPA treatment time window, many
stroke patients are still left with significant disability
[4, 5]. Endovascular thrombectomy (ET) is also effective
in acute ischemic stroke; however it must be started
within 6 h of stroke onset, less than 5–10 % of stroke
patients are eligible for treatment, and more than 50 %
remain with significant disability after ET [6]. It is,
therefore, essential to develop a neurorestorative and
neuroreparative treatment for ischemic stroke that could
be administered at a later time window since the current
time window of 3–6 h limits the number of stroke patients
whom can benefit [1, 2].
Cell therapy represents a treatment option for a wider
therapeutic time window in stroke patients by targeting
multiple reparative, anti-inflammatory, and cytoprotective
processes [6, 7] The cells can be administered through
intracerebral, intrathecal, intra-arterial, or intravenous
(IV) settings. Since the IV route is available in the com-
munity hospital setting, it is the most feasible method of
administration and the most likely to be disseminated
throughout the healthcare system. Despite the belief that
the IV route may not provide sufficient cells to the brain
due to the distribution to peripheral organs, cells that get
lodged into the lung and spleen appear to contribute to
the overall benefit from cell therapy. For example, after IV
delivery of MSCs, there is an improvement in cardiac
performance and reduction of myocardial damage as the
lungs trap MSCs and secrete the anti-inflammatory factor,
alpha inducible protein (TNFA1P6, or TSG-6) [7, 8].
Similarly, if hematopoietic stem cells and human umbilical
cord blood stem cells are delivered intravenously after
stroke [8–10], there is reduction in the transmigration of
splenocytes, counteracting both the acute inflammatory
injury to the brain and the later stroke-induced shrinking
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and “exhaustion” of the spleen that makes the patient
more vulnerable to infection [9–13]. Therefore, there may
be advantages to IV delivery versus the intracerebral or
intra-arterial methods.
The optimal time window for IV administration is
inconclusive, but it may extend out as far as 30 days
after the ischemic stroke [12, 14]. Specifically, the early,
‘tail end’ of the neuroprotective period in the time
period of about 24 h, presents a rich array of therapeutic
targets and an active period of brain remodeling that
could be exploited to salvage penumbral tissue and alter
inflammatory and immune responses, still evolving days
to weeks after the initial stroke [1, 2, 7].
Finding an effective and safe stem cell therapy for
stroke
Progenitor stem cells derived from bone marrow or pla-
cental tissue are advantageous in cell therapy because
they pose no ethical problems or concerns and few
safety concerns. Specifically, MSCs serve as a promising
form of cell therapy due to their anti-inflammatory and
immunomodulatory properties that permit the cells to
be transplanted in genetically dissimilar tissue [13–16].
This could lead to cell manufacture of allogeneic cells
from healthy unrelated donors (as opposed to autologous
cells), allowing a scalable and ‘off the shelf ’ stem cell
product, that requires no tissue matching.
MAPCs, originally discovered by Verfaillie et al. [15–19]
are a distinct adherent bone marrow population that are
able to differentiate into cells from all three varying germ
layers. After blastocyst injection, their multipotent nature
was confirmed by the presence of the cells in all tissues.
MAPCs can be isolated from either human or rodent bone
marrow, and the cells’ highly expandable nature allows for
the cells to be cryopreserved over extended periods and
subsequently thawed for clinical use [15, 19]. Early studies
showed the cells were effective in a rodent stroke model;
intracerebral transplantation of MAPC one-week after
cortical stroke resulted in the cells displaying a trophic
effect on the host brain that improved sensorimotor
ability [18, 20].
Athersys, Inc. has developed a clinical grade scale cell
therapy product called MultiStem [21] based on Verfaillie
et al. isolation procedure of MAPCs [15–19]. Multiple
preclinical studies investigating MultiStem’s adminis-
tration have provided insights into the cells’ mechanisms
of action, including neurotrophic and/or neuroprotective
improvements in animal models with neonatal hypoxic–
ischemic encephalopathy or focal ischemia [20–25] as
well as significant reduction in inflammatory cascades
and immune modulation in rodents with traumatic brain
injury and spinal cord injury [23, 24, 26–28].
There are many advantages of MultiStem for cell the-
rapy compared with other stem cells. In accordance with
Good Manufacturing Practice (GMP) conditions, Multi-
Stem have the potential to be manufactured in large
scale and in uniform clinical doses. Similarly, the nature
in which the MultiStem cells can be cryopreserved and
its subsequent use as an allogeneic product without
matching tissues, as noted by the preclinical research
completed by Athersys, would allow for easy distribution
to patients at appropriate times and dosages [19, 21].
MultiStem cells suppress mixed lymphocyte reactions
involving allogeneic T cells and peripheral blood cells
and are non-immunogenic [25, 29]. Similarly, in a rat
ischemic stroke model, MultiStem cells derived from
either rats or humans, when transplanted allogeneic and
xenogeneic cells, respectively, exhibited comparable level
of functional recovery without the use of immunosup-
pression [22].
In focal cerebral ischemia, MultiStem cells’ mechanism of
action is rooted in trophic and immunomodulatory actions
[26, 27, 30, 31]. While human MAPCs cause a reduction
in axonal dieback and the secretion of matrix metallo-
proteinase 9 (MMP-9), there is also a shift from the
pro-inflammatory state of M1 to an anti-inflammatory,
‘alternatively activated’ state of M2 in an in vitro axonal
dieback and an adult rat dorsal column crush model
[23, 26]. MAPCs are also effective at improving ischemic
limb function and preservation when delivered directly
into the tissue as observed in a model of limb ischemia
[24, 32]. Moreover, IV-administered MAPCs preserve
splenic mass when they migrate to the spleen and prevent
the increase in blood brain barrier permeability as shown
in a rodent model of traumatic brain injury [28]. A distinct
phenotypic feature of MAPCs over MSCs is their ability
to differentiate into endothelial cells and smooth muscles
[28, 29, 32, 33]. as well as their capability to secrete vascu-
lar endothelial growth factor (VEGF) and other angiogenic
molecules in vitro, and to increase vascular density in vivo
in a myocardial infarction model [30, 34].
Translation to the bedside
MultiStem cell-based therapy is a promising therapeutic
avenue for ischemic stroke. In acute myocardial infarction
and in prophylaxis of graft vs. host disease, MultiStem
cells have completed early phase clinical trials. MultiStem
cells that were administered in myocardium after coronary
intervention were well tolerated in a phase I trial of
patients with first ST-elevation [31, 35]. There was im-
provement in stroke volume 4 to 12 months after patients
were treated with a dose of about 50 million cells [31].
The MultiStem in Acute Stroke Treatment to Enhance
Recovery Study (MASTERS) is a multicenter, rando-
mized, double-blind, placebo-controlled trial of Multi-
Stem in acute ischemic stroke where MultiStem are
administered IV 24 to 48 h in moderate to moderate-
severe ischemic stroke patients [36]. ClinicalTrials.gov
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Identifier: NCT01436487. This trial demonstrated the
feasibility of administering a very large dose of cells IV
−1.2 billion per patient- a much higher dose than can be
achieved with other types of cell therapy. The study just
completed enrollment. Careful and rigorous preclinical
studies and limited clinical trials of MultiStem cells will
provide guidance into the safe and effective application of
cell therapy for stroke.
Conclusion
MultiStem are a promising cell therapy for ischemic
stroke. Their major mechanism of action is likely immu-
nomodulatory and they target the spleen and immune
system. Clinical trials to date show safety of MultStem.
The major advantages of clinical grade MultiStem are
scalability and “off the shelf” availability in a hospital phar-
macy with no requirement for tissue matching. If shown
effective in ongoing and future clinical trials in ischemic
stroke, MultiStem would have a wider time window allow-
ing more patients to benefit and would also be available
not only in academic medical centers but also in commu-
nity hospitals.
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